Table 2.

Comparison of anti-CL and anti-β2 GPI antibodies detected in ELISA and MLDA

anti-CL IgG		MLDA			anti-CL IgM		MLDA
		positive	negative	n			positive	negative	n
ELISA	positive	32	15	47	ELISA	positive	22	11	33
	negative	11	171	182		negative	20	176	196
	n	43	186	229		n	42	187	229
anti-β2 GPI IgG		MLDA			anti-β2 GPI IgM		MLDA
		positive	negative	n			positive	negative	n
ELISA	positive	24	3	27	ELISA	positive	21	16	37
	negative	7	195	202		negative	14	178	192
	n	31	198	229		n	35	194	229

Investigating 85 APS patients, 65 DC patients, and 79 NHS in ELISA and MDLA, no statistical difference could be detected for both techniques. According to the McNemar test, differences for anti-CL IgG (1.75%, 95% CI: -2.97% to 6.05%), anti-CL IgM (3.93%, 95% CI: -1.25% to 8.33%), anti-β2 GPI IgG (1.75%, 95 CI: -1.33% to 3.78%), and anti- β2 GPI IgM (0.87%, 95% CI: -4.11% to 5.67%) were not significant (P = 0.5563, P = 0.1508, P = 0.3438, and P = 0.1508, respectively). anti-β2 GPI, anti-beta2-glycoprotein I;

anti-CL, anti-cardiolipin; ELISA, enzyme-linked immunosorbent immunoassay; MLDA, multi-line dot assay.